uBriGene Biosciences Inc.

uBriGene Biosciences Inc. has established the integrated innovative CGT CDMO platforms that provide GMP-grade plasmid and T cell production services for large-scale CAR-T productions. We provide viral vectors, including adenovirus and lentivirus vectors to meet the demands of research and/or manufacturing applications. We are committed to driving innovation and accelerating cell and gene therapy development from target to market. With its fermentation capacity ranging from 5L to 500L, uBriGene offers a versatile selection of research grade, GMP-ready or GMP grade plasmids for research and clinical applications respectively. Our two-step purification technology allows fast and cost-effective cell harvesting process. uBriGene currently operates two state-of-the-art GMP facilities, including 21 clean suites with a total area of over 133,000 sq ft, and has produced 65 batches of GMP plasmids as of 2021. Since its founding, uBriGene has been providing one-stop service to fulfill comprehensive objectives of our clients, including some of the most cutting-edge leaders of the cell and gene therapy industry. We ensure the highest quality of products and services while striving to optimize for time and cost efficiency.